文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

使用质谱和核成像技术对(放射性)镧系元素的临床前比较:基于镧系元素的肿瘤靶向剂及离子形式镧系元素的生物分布

Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-12-16

本研究用ICP-MS同时检测镥、铽、钆、铕四种镧系元素,在体外肿瘤细胞摄取、小鼠体内生物分布及双同位素SPECT/CT中比较其作为DOTATATE、DOTA-LM3、PSMA-617和OxFol-1配合物或离子形式的差异。结果显示各镧系元素配合物的体外摄取和体内肿瘤摄取相似,而离子形式在肝和骨的分布因离子半径不同而异。

要点

  • 四种镧系元素与同一生物分子形成的配合物体外细胞摄取和体内肿瘤摄取相似。
  • Ln-DOTATATE和Ln-DOTA-LM3在AR42J肿瘤1小时摄取分别为3.8‒5.1% ID/g和4.5‒5.0% ID/g。
  • 离子形式镧系元素在肝和骨的分布因离子半径不同而有差异。

核心结论

  • 研究证实镧系元素配合物性质相似,提示镥-177可能可被其他放射性镧系元素替代,且很可能不影响所得放射性药物的组织分布特征。
  • 另一方面,当以未络合形式注射时,镧系元素离子半径的差异影响其在肝和骨中的摄取与再吸收机制。

研究设计与样本

  • 采用电感耦合等离子体质谱(ICP-MS)同时检测生物样本中的四种镧系元素(镥、铽、钆、铕)。
  • 用Ln-DOTATATE、Ln-DOTA-LM3、Ln-PSMA-617和Ln-OxFol-1进行体外肿瘤细胞摄取和体内生物分布研究。
  • 体外及体内研究使用表达生长抑素受体、前列腺特异性膜抗原和叶酸受体的AR42J、PC-3 PIP和KB细胞及相应肿瘤小鼠模型。
  • 在免疫健全小鼠中研究离子形式镧系元素的分布。
  • 用镥-177和铽-161标记的生物分子或氯化物盐对小鼠进行双同位素SPECT/CT成像研究。

主要发现

  • 每种生物分子的四种镧系元素配合物在相应肿瘤细胞系中的体外细胞摄取相似。
  • 小鼠中Ln-DOTATATE和Ln-DOTA-LM3在AR42J肿瘤的摄取在1小时分别为3.8‒5.1% ID/g和4.5‒5.0% ID/g,各镧系元素配合物相似。
  • Ln-PSMA-617在PC-3 PIP肿瘤的1小时累积为24-25% ID/g,Ln-OxFol-1在KB肿瘤的24小时累积为28-31% ID/g,每种生物分子的四种镧系元素配合物相等。
  • 注射镧系元素氯化物盐(LnCl3;Ln = natLu、natTb、natGd、natEu)后,24小时肝摄取分别为~12% ID/g、~22% ID/g、~31% ID/g和~37% ID/g,可归因于各镧系元素离子的半径。
  • 骨中镥的累积明显高于其他镧系元素(24小时:25 ± 5% ID/g vs. 14‒15% ID/g),177Lu/161Tb双同位素SPECT/CT图像视觉上证实了这些数据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With the growing interest in exploring radiolanthanides for nuclear medicine applications, the question arises as to whether they are generally interchangeable without affecting a biomolecule's pharmacokinetic properties. The goal of this study was to investigate similarities and differences of four (radio)lanthanides simultaneously applied as complexes of biomolecules or in ionic form. METHODS: Inductively coupled plasma mass spectrometry (ICP-MS) was employed for the simultaneous detection of four lanthanides (Ln = lutetium, terbium, gadolinium and europium) in biological samples. In vitro tumor cell uptake and in vivo biodistribution studies were performed with Ln-DOTATATE, Ln-DOTA-LM3, Ln-PSMA-617 and Ln-OxFol-1. AR42J cells, PC-3 PIP cells and KB cells expressing the somatostatin receptor, the prostate-specific membrane antigen and the folate receptor, respectively, were used in vitro as well as to obtain the respective tumor mouse models for in vivo studies. The distribution of lanthanides in ionic form was investigated in immunocompetent mice. Dual-isotope SPECT/CT imaging studies were performed with mice administered with the radiolabeled biomolecules or chloride salts of lutetium-177 and terbium-161. RESULTS: Similar in vitro cell uptake was observed for all four lanthanide complexes of each biomolecule into the respective tumor cell lines. AR42J tumor uptake of Ln-DOTATATE and Ln-DOTA-LM3 in mice showed similar values for all lanthanide complexes (3.8‒5.1% ID/g and 4.5‒5.0% ID/g; 1 h p.i., respectively). Accumulation of Ln-PSMA-617 in PC-3 PIP tumors (24-25% ID/g; 1 h p.i.) and of Ln-OxFol-1 in KB tumors (28-31% ID/g; 24 h p.i.) were also equal for the four lanthanide complexes of each biomolecule. After injection of lanthanide chloride salts (LnCl3; Ln = natLu, natTb, natGd, natEu), the liver uptake was different for each metal (~ 12% ID/g, ~ 22% ID/g, ~ 31% ID/g and ~ 37% ID/g; 24 h p.i., respectively) which could be ascribed to the radii of the respective lanthanide ions. In the bones, accumulation was considerably higher for lutetium than for other lanthanides (25 ± 5% ID/g vs. 14‒15% ID/g; 24 h p.i.). These data were confirmed visually by 177Lu/161Tb-based dual-isotope SPECT/CT images. CONCLUSIONS: The presented study confirmed similar properties of Ln-complexes, suggesting that lutetium-177 can be replaced by other radiolanthanides, most probably without affecting the tissue distribution profile of the resultant radiopharmaceuticals. On the other hand, the different radii of the lanthanide ions affected their uptake and resorption mechanisms in liver and bones when injected in uncomplexed form.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wallimann RH, Mehta A, Mapanao AK, et al. Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. Eur J Nucl Med Mol Imaging. 2024. PMID: 39680064. doi:10.1007/s00259-024-07018-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。